B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

RYR3

MOLECULAR TARGET

ryanodine receptor 3

UniProt: Q15413NCBI Gene: 62634 compounds

RYR3 (ryanodine receptor 3) is targeted by 4 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting RYR3

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1Caffeine0.691
2Adenosine Triphosphate0.691
3Dantrolene Skeletal muscle relaxant that acts by interfering with excitation-contraction coupling in0.691
4Ryanodine0.691

About RYR3 as a Drug Target

RYR3 (ryanodine receptor 3) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 4 compounds with documented RYR3 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

RYR3 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.